German chemicals and pharmaceuticals giant Bayer, maker of Aspirin, said yesterday it turned in a better first quarter performance than expected thanks to healthy growth driven by new products.
The group based in the western town of Leverkusen said in a statement that bottom-line net profit grew by 23% to €1.42bn ($1.96bn) between January and March.
Analysts polled by Dow Jones Newswires had expected a just seven-percent rise. Turnover climbed 2.8% to €10.6bn during the same period. “We are confident about our business development for the rest of the year and confirm our outlook for 2014,” chief executive Marijn Dekkers said in a statement. She cited the pharmaceutical products on the market for providing a boost.
The company said that it was counting on annual turnover of around €41bn, up about 2% on the year.
Underlying or operating profit, as measured by earnings before interest, tax, depreciation and amortisation (EBITDA), is expected to rise 5%.
Bayer said its first-quarter results had been powered by robust business for its healthcare and agrochemical divisions and an improvement in its material science division.Last updated:
LEAVE A COMMENT Your email address will not be published. Required fields are marked*
Chamber processes 52% of its transactions online in 2020
Qatar to offer more tourism, shopping opportunities, says business leader
Swiss authorities ask Lebanon to co-operate on central bank probe
India plans foreign investment ‘rule changes that could hit Amazon’
Global equities mixed ahead of Biden’s inauguration
Asia shares edge higher before Yellen, on eve of Biden inauguration
Masraf Al Rayan posts QR2.17bn net profit in 2020
Qatar wealth fund plans Asia Push with focus still on US